UNDERWRITER COMMON SHARE PURCHASE WARRANT IMMUNOPRECISE ANTIBODIES LTD.ImmunoPrecise Antibodies Ltd. • February 4th, 2021 • Pharmaceutical preparations • New York
THIS UNDERWRITER COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after February 8, 2021 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on February 3, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from ImmunoPrecise Antibodies Ltd. (the “Company”), a corporation incorporated under the Business Corporations Act (British Columbia) up to ______ common shares (as subject to adjustment hereunder, the “Warrant Shares”) in the capital of the Company. The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain Amended and Restated Underwriting Agreement, by and between the Company and H.C. Wainwright & Co.,
AMENDED AND RESTATED UNDERWRITING AGREEMENTUnderwriting Agreement • February 4th, 2021 • ImmunoPrecise Antibodies Ltd. • Pharmaceutical preparations • New York
This Lock-Up Agreement (this “Agreement”) is being delivered to you in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”) between ImmunoPrecise Antibodies Ltd., a corporation incorporated under the Business Corporations Act (British Columbia) (the “Company”), and H.C. Wainwright & Co. LLC (“Wainwright”), as manager of a group of underwriters (collectively, the “Underwriters”), to be named therein, and the other parties thereto (if any), relating to the proposed public offering of common shares (the “Common Shares”), of the Company.
